Skip to main content

Advertisement

Log in

Stage III Thick (>4.0 mm) Lower Extremity Melanoma: Is Timing of Lymph Node Involvement a Prognostic Factor?

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Purpose

The prognosis for stage III melanoma patients is mixed, and there is need for new prognostic factors to be incorporated into a revision of melanoma TNM staging. We analyzed the possible role of the timing of lymph node involvement as an important prognostic factor.

Methods

Among 249 melanoma patients who underwent ilioinguinal lymphadenectomy, a group of 185 patients with a thick (>4mm) melanoma and full clinical data available was analyzed. The mean depth of invasion was 5.85 mm; the tumor was ulcerated in 67 cases (36.2%); and Clark V was diagnosed in 82 patients (44.3%). The median interval between primary excision and the time of lymphadenectomy was 11.1 months.

Results

Recurrent disease was reported in 150 of 185 patients. The first sites of recurrence were the skin in 15.7%, lymph nodes in 13.5%, and distant metastases in 28.7%; the remaining 43 patients (23.2%) had multifocal recurrences. In all, 35 patients (18.9%) were disease-free. Skip metastases (positive iliac and negative inguinal lymph nodes) were found in 26 patients (14%). Multivariate Cox analysis showed that only the time between the first surgery and lymphadenectomy and the number of involved nodes were significant predictors of survival. Relative risk of death was 5.2 times higher for patients who had simultaneously undergone lymphadenectomy (compared to lymph dissection performed >1 year after primary excision) and about 2.7 times higher for those with more regionally advanced disease (pN3 vs. pN1).

Conclusions

The long disease-free interval before the development of lymph node metastases and before node dissection is a favorable prognostic factor independent of other well known parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wagner JD, Gordon MS, Chuang TY et al (2000) Current therapy of cutaneous melanoma. Plast Reconstr Surg 105:1956–1966

    Article  PubMed  CAS  Google Scholar 

  2. Gershenwald JE, Thompson W, Mansfield PF et al (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976–983

    PubMed  CAS  Google Scholar 

  3. Gershenwald JE, Prieto V, Colome-Grimmer MI et al (2000) The prognostic significance of microscopic tumor burden in 925 melanoma patients undergoing sentinel lymph node biopsy. Proc Am Soc Clin Oncol 19:551a

    Google Scholar 

  4. Balch CM, Buzaid AC, Atkins MB et al (2000) A new American Joint Committee on cancer staging system for cutaneous melanoma. Cancer 88:1484–1491

    Article  PubMed  CAS  Google Scholar 

  5. Balch C, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol 19:3622–3634

    PubMed  CAS  Google Scholar 

  6. Buzaid AC, Ross MI, Balch CM et al (1997) Critical analysis of the current American Joint Committee on cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15:1039–1051

    PubMed  CAS  Google Scholar 

  7. Kissin MW, Simpson DA, Easton D et al (1987) Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 74:1023–1026

    Article  PubMed  CAS  Google Scholar 

  8. Mack LA, McKinnon JG (2004) Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 86:189–199

    Article  PubMed  Google Scholar 

  9. Kretschmer L, Neumann C, Preusser KP et al (2001) Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin: an analysis of survival and local recurrence. Acta Oncol 40:72–78

    Article  PubMed  CAS  Google Scholar 

  10. Zettersten E, Sagebiel RW, Miller JR et al (2002) Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 94:1049–1056

    Article  PubMed  Google Scholar 

  11. Paek SC, Griffith KA, Johnson TM et al (2007) The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109:100–108

    Article  PubMed  Google Scholar 

  12. Balch CM, Wilkerson JA, Murad TM et al (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45:3012–3017

    Article  PubMed  CAS  Google Scholar 

  13. Harrist TJ, Rigel DS, Day CL Jr et al (1984) “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53:2183–2187

    Article  PubMed  CAS  Google Scholar 

  14. Leon P, Daly JM, Synnestvedt M et al (1991) The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 126:1461–1468

    PubMed  CAS  Google Scholar 

  15. Eton O, Legha SS, Moon TE et al (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103–1111

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Krzysztof Herman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herman, K., Wysocki, W.M., Skotnicki, P. et al. Stage III Thick (>4.0 mm) Lower Extremity Melanoma: Is Timing of Lymph Node Involvement a Prognostic Factor?. World J Surg 33, 469–474 (2009). https://doi.org/10.1007/s00268-008-9895-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-008-9895-z

Keywords

Navigation